Protagenic Therapeutics(PTIX)
$0.48-0.01 (-1.83%)
PTIX
Protagenic Therapeutics financials statements
$0.48
At close:-0.01 (-1.83%)
Want to see PTIX full AI Analyst Report?
Protagenic Therapeutics (PTIX) Ratios
98 Followers
Protagenic Therapeutics Ratios
PTIX's free cash flow for Q3 2026 was $-488.89K. For the 2026 fiscal year, PTIX's free cash flow was increased by $0.00 and operating cash flow was $-488.89K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.34 | 2.00 | 6.41 | 7.18 | 13.83 |
| Quick Ratio | 0.34 | 2.00 | 6.41 | 7.18 | 13.83 |
| Cash Ratio | 0.32 | 1.95 | 1.97 | 0.19 | 0.68 |
| Solvency Ratio | -0.75 | -5.81 | -7.59 | -3.18 | -4.05 |
| Operating Cash Flow Ratio | -0.61 | -4.47 | -5.65 | -1.78 | -3.50 |
| Short-Term Operating Cash Flow Coverage | -1.31 | 0.00 | 0.00 | -5.79 | 0.00 |
| Net Current Asset Value | $ -4.52M | $ 940.11K | $ 3.54M | $ 6.92M | $ 9.94M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.48 | 0.00 | 0.00 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | -1.32 | 0.00 | 0.00 | 0.05 | 0.03 |
| Debt-to-Capital Ratio | 4.13 | 0.00 | 0.00 | 0.05 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Financial Leverage Ratio | -0.89 | 1.93 | 1.18 | 1.16 | 1.11 |
| Debt Service Coverage Ratio | -2.06 | 0.00 | -41.78 | -7.10 | -8.33 |
| Interest Coverage Ratio | -19.64 | 0.00 | -42.04 | -25.88 | -8.33 |
| Debt to Market Cap | 1.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.78 | 0.00 | 0.02 | 0.11 | 0.22 |
| Net Debt to EBITDA | -0.13 | 0.34 | 0.29 | -0.04 | 0.05 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.42% | 96.91% | 110.45% | 99.94% | 109.25% |
| Return on Assets (ROA) | -241.84% | -282.48% | -115.65% | -44.24% | -40.90% |
| Return on Equity (ROE) | 215.50% | -545.33% | -136.31% | -51.41% | -45.49% |
| Return on Capital Employed (ROCE) | 124.29% | -562.70% | -123.41% | -51.43% | -40.35% |
| Return on Invested Capital (ROIC) | 379.69% | -562.70% | -123.41% | -49.00% | -40.35% |
| Return on Tangible Assets | -13276.99% | -282.48% | -115.65% | -44.24% | -40.90% |
| Earnings Yield | -204.99% | -16.44% | -8.30% | -3.68% | -1.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.49 | 0.25 | 0.00 | 0.00 |
| Inventory Turnover | 35.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19637.48 | -747.35 | -1472.03 | -1891746.33 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 10.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 19647.88 | 747.35 | 1472.03 | 1891746.33 | 0.00 |
| Operating Cycle | 10.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.14 | -0.86 | -0.85 | -0.46 | -0.76 |
| Free Cash Flow Per Share | -2.14 | -0.86 | -0.89 | -0.46 | -0.76 |
| Dividend Paid and CapEx Coverage Ratio | -1380116.67 | 0.00 | -24.73 | -1104.61 | -699653.50 |
| Capital Expenditure Coverage Ratio | -1380116.67 | 0.00 | -24.73 | -1104.61 | -699653.50 |
| Operating Cash Flow Coverage Ratio | -1.31 | 0.00 | 0.00 | -5.79 | -8.79 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -164.60% | -12.54% | -6.40% | -2.06% | -0.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.38 | -6.07 | -12.04 | -27.20 | -63.19 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -1.05 | 33.18 | 16.42 | 13.98 | 28.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.61 | -7.97 | -15.63 | -48.47 | -102.13 |
| Price-to-Operating Cash Flow Ratio | -0.61 | -7.97 | -16.26 | -48.51 | -102.13 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 3.49 | -0.30 | 0.80 | -2.63 |
| Enterprise Value Multiple | -0.49 | -5.80 | -13.10 | -28.34 | -68.99 |
| Enterprise Value | 3.46M | 31.78M | 58.93M | 96.85M | 285.59M |
| EV to EBITDA | -0.49 | -5.80 | -13.10 | -28.34 | -68.99 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.84 | -7.54 | -15.29 | -48.53 | -102.05 |
| EV to Operating Cash Flow | -0.84 | -7.54 | -15.91 | -48.58 | -102.05 |
| Tangible Book Value Per Share | -3.51 | 0.21 | 0.84 | 1.60 | 2.70 |
| Shareholders’ Equity Per Share | -1.24 | 0.21 | 0.84 | 1.60 | 2.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.66 | -1.13 | -1.15 | -0.82 | -1.23 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.72 | 1.00 | 1.10 | 1.04 | 1.09 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.76 | 0.74 | 0.56 | 0.62 |
Currency in USD
